The Food and Drug Administration (FDA) has updated the labeling for Kisunla ™ (donanemab-azbt) to include a new recommended titration dosing schedule for adults with early symptomatic Alzheimer ...

The benefit-risk balance is tipping more in favor of Eli Lilly’s Kisunla in early Alzheimer’s disease as the FDA ...

Approval was based on results from the Phase IIIb TRAILBLAZER-ALZ 6 trial, which showed that Kisunla achieved comparable ...

A slower ramp-up of Kisunla dosing lowers the rate of dangerous brain swelling, a risk that has made doctors reluctant to ...

Kisunla™ (kih-SUHN-lah) is used to treat adults with early symptomatic Alzheimer's disease (AD), which includes mild cognitive impairment (MCI) or mild dementia stage of disease.

Lilly's Kisunla gets FDA approval for a new dosing schedule that significantly lowers ARIA-E risk while maintaining amyloid ...

Saturday at the Dream Center, the Bismarck Memory Cafe hosted a presentation from the Alzheimer’s Association about recent ...

A journey through the FDA’s newly released complete response letters gave glimpses into the journeys to market for Eli ...

Eli Lilly and Company (LLY) announced on Wednesday that the U.S. Food and Drug Administration (FDA) has approved a label ...

Kisunla is a newer treatment that works to slow down how fast Alzheimer’s progresses. It contains an antibody called donanemab-azbt, which targets and clears amyloid from the brain.

Kisunla is a prescription drug used to treat Alzheimer's disease. Find out whether it interacts with other drugs, alcohol, supplements, and more.

Kisunla (donanemab-azbt) is a prescription drug that’s used to treat Alzheimer’s disease in adults. Kisunla is given as an intravenous (IV) infusion by a doctor or other healthcare professional.